← Leaderboards
Haval Shirwan
University Of Missouri-Columbia
$11,979,492
Attributed
$20,379,140
Total exposure
21
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,379,140 · 21
By mechanism
R01$8,425,558 · 4
R21$2,919,056 · 6
U01$2,012,531 · 1
R44$1,771,799 · 1
R41$1,729,223 · 5
T32$1,621,256 · 2
Top collaborators
- Andres J Garcia21 shared
- Esma S Yolcu7 shared
- Suzanne T Ildstad5 shared
- Kathryn J. Macleod5 shared
- Devin E Eckhoff3 shared
- Matthew Lawrenz3 shared
- Ji Lei3 shared
- James F Markmann3 shared
Most similar at University Of Missouri-Columbia
Same institution · by research overlap
- Wendy L Picking$15,895,808
- Deborah M Anderson$5,225,128
Others in their field
Top investigators on “Immune”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$541,067,641
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$470,748,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Judith S. Currier · University Of California Los Angeles$334,425,492
Research focus
ImmuneCellsPreventClinical TrialsMouse ModelSignal TransductionChronicInsulinEngineeringImmunoregulationInsulin-Dependent Diabetes MellitusIsletIslets Of Langerhans TransplantationTransplantationAffectNonhuman PrimateAutoimmune DiseasesInnovationDiabeticResponseHumanized MouseTranslationsStreptavidinGraft Survival
Grant awards (59)
Hydrogels for human beta cell survival, function and evasion of immune rejection$784,733
R01 · FY2025 · DK
Developing a novel agonist of CD137 for cancer immunoprevention$761,094
UG3 · FY2025 · CA · contact PI
BIOMATERIALS FOR STEM CELL-DERIVED BETA CELL TRANSPLANTATION$250,384
R01 · FY2025 · DK
Hydrogels for human beta cell survival, function and evasion of immune rejection$785,689
R01 · FY2024 · DK
Developing a novel agonist of CD137 for cancer immunoprevention$761,094
UG3 · FY2024 · CA · contact PI
BIOMATERIALS FOR STEM CELL-DERIVED BETA CELL TRANSPLANTATION$422,084
R01 · FY2024 · DK
A novel immunomodulatory approach to overcome innate and adaptiveimmune barriers to islet transplantation$380,297
R01 · FY2024 · AI · contact PI
Hydrogels for human beta cell survival, function and evasion of immune rejection$82,702
R01 · FY2024 · DK
Hydrogels for human beta cell survival, function and evasion of immune rejection$772,871
R01 · FY2023 · DK
BIOMATERIALS FOR STEM CELL-DERIVED BETA CELL TRANSPLANTATION$420,185
R01 · FY2023 · DK
A novel immunomodulatory approach to overcome innate and adaptiveimmune barriers to islet transplantation$394,300
R01 · FY2023 · AI · contact PI
Hydrogels for human beta cell survival, function and evasion of immune rejection$82,702
R01 · FY2023 · DK
BIOMATERIALS FOR STEM CELL-DERIVED BETA CELL TRANSPLANTATION$59,404
R01 · FY2023 · DK
Hydrogels for human beta cell survival, function and evasion of immune rejection$822,338
R01 · FY2022 · DK
BIOMATERIALS FOR STEM CELL-DERIVED BETA CELL TRANSPLANTATION$394,972
R01 · FY2022 · DK
BIOMATERIALS FOR STEM CELL-DERIVED BETA CELL TRANSPLANTATION$79,766
R01 · FY2022 · DK
BIOMATERIALS FOR STEM CELL DERIVED BETA CELL TRANSPLANTATION$19,801
R01 · FY2022 · DK
Targeted delivery of immunomodulatory biologics for induction of immune privilege to allogeneic pancreatic islet grafts$420,968
U01 · FY2021 · AI · contact PI
BIOMATERIALS FOR STEM CELL-DERIVED BETA CELL TRANSPLANTATION$407,582
R01 · FY2021 · DK
A novel immunomodulatory approach to overcome innate and adaptiveimmune barriers to islet transplantation$373,065
R01 · FY2021 · AI · contact PI
Targeted delivery of immunomodulatory biologics for induction of immune privilege to allogeneic pancreatic islet grafts$413,601
U01 · FY2020 · AI · contact PI
A novel immunomodulatory approach to overcome innate and adaptiveimmune barriers to islet transplantation$372,323
R01 · FY2020 · AI · contact PI
Establishing immunoprivileged scaffolds for transplantation of immature beta cells$193,750
R21 · FY2020 · AI
Targeted delivery of immunomodulatory biologics for induction of immune privilege to allogeneic pancreatic islet grafts$388,154
U01 · FY2019 · AI · contact PI
A novel immunomodulatory approach to overcome innate and adaptive immune barriers to islet transplantation$376,360
R01 · FY2019 · AI · contact PI
Establishing immunoprivileged scaffolds for transplantation of immature beta cells$246,500
R21 · FY2019 · AI
Targeted delivery of immunomodulatory biologics for induction of immune privilege to allogeneic pancreatic islet grafts$388,154
U01 · FY2018 · AI · contact PI
Inflammation and Pathogenesis Training Program$68,676
T32 · FY2018 · AI · contact PI
Targeted delivery of immunomodulatory biologics for induction of immune privilege to allogeneic pancreatic islet grafts$401,654
U01 · FY2017 · AI · contact PI
A novel immunomodulatory approach to overcome innate and adaptive immune barriers to islet transplantation$377,529
R56 · FY2016 · AI · contact PI
Developing a novel adjuvant system for therapeutic vaccines against lung cancer$225,000
R41 · FY2016 · CA · contact PI
Immuno-vasculogenic hydrogels for islet engraftment and localized tolerance$221,123
R21 · FY2016 · EB · contact PI
Improving the lead rF1-V plague vaccine using an SA-4-1BBL/alum adjuvant platform$187,500
R21 · FY2016 · AI · contact PI
Engineering pancreatic islets with TGβ protein to overcome rejection$187,500
R21 · FY2016 · AI · contact PI
Improving the lead rF1-V plague vaccine using an SA-4-1BBL/alum adjuvant platform$225,000
R21 · FY2015 · AI · contact PI
Engineering pancreatic islets with TGβ protein to overcome rejection$225,000
R21 · FY2015 · AI · contact PI
Improving the therapeutic efficacy of a lead vaccine against plague using a novel adjuvant system$224,999
R41 · FY2015 · AI · contact PI
Immuno-vasculogenic hydrogels for islet engraftment and localized tolerance$196,683
R21 · FY2015 · EB · contact PI
Training Program in Transplantation$94,430
T32 · FY2013 · HL
Training Program in Transplantation$366,522
T32 · FY2012 · HL
Training Program in Transplantation$531,030
T32 · FY2011 · HL
ApoFasL as a novel treatment for Type 1 Diabetes in Nonhuman Primates$399,912
R41 · FY2011 · DK
ApoFasL as a novel treatment for Type 1 Diabetes in Nonhuman Primates$47,088
R41 · FY2011 · DK
ApoFasL as a novel treatment for Type 1 Diabetes in Nonhuman Primates$403,924
R41 · FY2010 · DK
Training Program in Transplantation$336,014
T32 · FY2010 · HL
ApoVax104-HPV as a Novel Vaccine for Cervical Cancer$852,358
R44 · FY2009 · AI
Training Program in Transplantation$224,584
T32 · FY2009 · HL
ApoVax104-HPV as a Novel Vaccine for Cervical Cancer$919,441
R44 · FY2008 · AI
ApoVax-SVN as a Novel Vaccine for Cancer Immunotherapy$328,300
R41 · FY2007 · CA · contact PI
A Novel Approach to Prevent and Treat Type 1 Diabetes$294,000
R21 · FY2005 · AI
Allograft Tolerance with Fas/FasL-Mediated Apoptosis$286,000
R01 · FY2005 · AI
A Novel Approach to Prevent and Treat Type 1 Diabetes$294,000
R21 · FY2004 · AI
Allograft Tolerance with Fas/FasL-Mediated Apoptosis$286,000
R01 · FY2004 · AI
A NOVEL ADJUVANT FOR TUMQR VACCINATION$100,000
R41 · FY2004 · CA
Allograft Tolerance with Fas/FasL-Mediated Apoptosis$286,000
R01 · FY2003 · AI
APOPTOSIS:A MEANS OF IMMUNE REGULATION TO TREAT DIABETES$216,000
R21 · FY2003 · DK
Allograft Tolerance with Fas/FasL-Mediated Apoptosis$286,000
R01 · FY2002 · AI
APOPTOSIS:A MEANS OF IMMUNE REGULATION TO TREAT DIABETES$216,000
R21 · FY2002 · DK
APOPTOSIS:A MEANS OF IMMUNE REGULATION TO TREAT DIABETES$216,000
R21 · FY2001 · DK